SKA1 regulates the metastasis and cisplatin resistance of non-small cell lung cancer

Shen,Lihua; Yang,Min; Lin,Qionghua; Zhang,Zhongwei; Miao,Changhong; Zhu,Biao

doi:10.3892/or.2016.4670

SKA1 regulates the metastasis and cisplatin resistance of non-small cell lung cancer

Authors:
- Lihua Shen
- Min Yang
- Qionghua Lin
- Zhongwei Zhang
- Changhong Miao
- Biao Zhu
View Affiliations

Affiliations: Department of Anaesthesia, Critical Care and Pain Medicine, Fudan University Shanghai Cancer Center, Shanghai 200032, P.R. China, Department of Respiratory Diseases, Tianjin First Center Hospital, Tianjin 300192, P.R. China
Published online on: March 10, 2016 https://doi.org/10.3892/or.2016.4670
Pages: 2561-2568
Copyright: © Shen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Currently, chemotherapy with platinum-based drugs including cisplatin is the most effective therapy for the treatment of non-small cell lung carcinoma (NSCLC). However, the efficacy of chemotherapy is limited due to commonly developed drug resistance. Spindle and kinetochore-associated complex subunit 1 (SKA1) is part of a complex essential for stabilizing the attachment of spindle microtubules to kinetochores and for maintaining the metaphase plate during mitosis. In the present study, we aimed to investigate the role of SKA1 in the process of metastasis and drug resistance of NSCLC. We completed a series of experiments to investigate the function of SKA1 in NSCLC metastasis and drug resistance including qRT-PCR, immunohistochemistry and western blotting, as well as MTT, BrdU, wounded healing, Transwell and gelatin zymography assays. We demonstrated that the expression levels of SKA1 were elevated in NSCLC and were correlated with cancer progression and malignancy. We also reported that SKA1 positively regulated the proliferation and metastatic ability of NSCLC cells. In addition, we determined that SKA1 contributed to cisplatin resistance in NSCLC cells by protecting these cells from cisplatin-induced cell apoptosis. SKA1 also appeared to regulate the ERK1/2 and the Akt-mediated signaling pathways in NSCLC cells. SKA1 is required for metastasis and cisplatin resistance of non-small cell lung cancer.

View Figures

View References

1	Cersosimo RJ: Lung cancer: A review. Am J Health Syst Pharm. 59:611–642. 2002.PubMed/NCBI
2	Parsons A, Daley A, Begh R and Aveyard P: Influence of smoking cessation after diagnosis of early stage lung cancer on prognosis: Systematic review of observational studies with meta-analysis. BMJ. 340:b55692010. View Article : Google Scholar : PubMed/NCBI
3	Sakashita S, Sakashita M and Sound Tsao M: Genes and pathology of non-small cell lung carcinoma. Semin Oncol. 41:28–39. 2014. View Article : Google Scholar : PubMed/NCBI
4	Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, Castedo M and Kroemer G: Molecular mechanisms of cisplatin resistance. Oncogene. 31:1869–1883. 2012. View Article : Google Scholar
5	Trédan O, Galmarini CM, Patel K and Tannock IF: Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst. 99:1441–1454. 2007. View Article : Google Scholar : PubMed/NCBI
6	Dasari S and Tchounwou PB: Cisplatin in cancer therapy: Molecular mechanisms of action. Eur J Pharmacol. 740:364–378. 2014. View Article : Google Scholar : PubMed/NCBI
7	Zhang B, Li KY, Chen HY, Pan SD, Jiang LC, Wu YP and Liu SW: Spindle and kinetochore associated complex subunit 1 regulates the proliferation of oral adenosquamous carcinoma CAL-27 cells in vitro. Cancer Cell Int. 13:832013. View Article : Google Scholar : PubMed/NCBI
8	Qin X, Yuan B, Xu X, Huang H and Liu Y: Effects of short interfering RNA-mediated gene silencing of SKA1 on proliferation of hepatocellular carcinoma cells. Scand J Gastroenterol. 48:1324–1332. 2013. View Article : Google Scholar : PubMed/NCBI
9	Tian F, Xing X, Xu F, Cheng W, Zhang Z, Gao J, Ge J and Xie H: Downregulation of SKA1 gene expression inhibits cell growth in human bladder cancer. Cancer Biother Radiopharm. 30:271–277. 2015. View Article : Google Scholar : PubMed/NCBI
10	Sun W, Yao L, Jiang B, Guo L and Wang Q: Spindle and kinetochore-associated protein 1 is overexpressed in gastric cancer and modulates cell growth. Mol Cell Biochem. 391:167–174. 2014. View Article : Google Scholar : PubMed/NCBI
11	Li J, Xuan JW, Khatamianfar V, Valiyeva F, Moussa M, Sadek A, Yang BB, Dong BJ, Huang YR and Gao WQ: SKA1 over-expression promotes centriole over-duplication, centrosome amplification and prostate tumourigenesis. J Pathol. 234:178–189. 2014.PubMed/NCBI
12	Dong C, Wang XL and Ma BL: Expression of spindle and kinetochore-associated protein 1 is associated with poor prognosis in papillary thyroid carcinoma. Dis Markers. 2015:6165412015. View Article : Google Scholar : PubMed/NCBI
13	Shi X, Chen X, Peng H, Song E, Zhang T, Zhang J, Li J, Swa H, Li Y, Kim S, et al: Lentivirus-mediated silencing of spindle and kinetochore-associated protein 1 inhibits the proliferation and invasion of neuronal glioblastoma cells. Mol Med Rep. 11:3533–3538. 2015.PubMed/NCBI
14	Gaitanos TN, Santamaria A, Jeyaprakash AA, Wang B, Conti E and Nigg EA: Stable kinetochore-microtubule interactions depend on the Ska complex and its new component Ska3/C13Orf3. EMBO J. 28:1442–1452. 2009. View Article : Google Scholar : PubMed/NCBI
15	Raaijmakers JA, Tanenbaum ME, Maia AF and Medema RH: RAMA1 is a novel kinetochore protein involved in kinetochore-microtubule attachment. J Cell Sci. 122:2436–2445. 2009. View Article : Google Scholar : PubMed/NCBI
16	Theis M, Slabicki M, Junqueira M, Paszkowski-Rogacz M, Sontheimer J, Kittler R, Heninger AK, Glatter T, Kruusmaa K, Poser I, et al: Comparative profiling identifies C13orf3 as a component of the Ska complex required for mammalian cell division. EMBO J. 28:1453–1465. 2009. View Article : Google Scholar : PubMed/NCBI
17	Hanisch A, Silljé HH and Nigg EA: Timely anaphase onset requires a novel spindle and kinetochore complex comprising Ska1 and Ska2. EMBO J. 25:5504–5515. 2006. View Article : Google Scholar : PubMed/NCBI
18	Wang M, Liu ZM, Li XC, Yao YT and Yin ZX: Activation of ERK1/2 and Akt is associated with cisplatin resistance in human lung cancer cells. J Chemother. 25:162–169. 2013. View Article : Google Scholar : PubMed/NCBI
19	Chen TJ, Zhou YF, Ning JJ, Yang T, Ren H, Li Y, Zhang S and Chen MW: NBM-T-BMX-OS01, an osthole derivative, sensitizes human lung cancer A549 cells to cisplatin through AMPK-dependent inhibition of ERK and Akt Pathway. Cell Physiol Biochem. 36:893–906. 2015. View Article : Google Scholar : PubMed/NCBI
20	Stinchcombe TE and Johnson GL: MEK inhibition in non-small cell lung cancer. Lung Cancer. 86:121–125. 2014. View Article : Google Scholar : PubMed/NCBI
21	Yip PY: Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin (PI3K-Akt-mTOR) signaling pathway in non-small cell lung cancer. Transl Lung Cancer Res. 4:165–176. 2015.PubMed/NCBI